Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells.

Benakanakere I, Johnson T, Sleightholm R, Villeda V, Arya M, Bobba R, Freter C, Huang C.

Exp Hematol Oncol. 2014 Sep 26;3:24. doi: 10.1186/2162-3619-3-24. eCollection 2014.

2.

The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.

Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM.

Int J Oncol. 2013 Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24.

3.

Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats.

Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1316-24. doi: 10.1158/1940-6207.CAPR-10-0382. Epub 2011 Apr 19.

4.

Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in sprague-dawley rats.

Benakanakere I, Besch-Williford C, Carroll CE, Hyder SM.

Cancer Prev Res (Phila). 2010 Sep;3(9):1157-67. doi: 10.1158/1940-6207.CAPR-10-0064. Epub 2010 Aug 10.

5.

Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells.

Mafuvadze B, Benakanakere I, Hyder SM.

Menopause. 2010 Sep-Oct;17(5):1055-63. doi: 10.1097/gme.0b013e3181dd052f.

PMID:
20551847
6.

Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice.

Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM.

Menopause. 2010 Sep-Oct;17(5):1040-7. doi: 10.1097/gme.0b013e3181d3dd0c.

7.

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM.

Breast Cancer Res Treat. 2011 Jan;125(2):407-20. doi: 10.1007/s10549-010-0851-x. Epub 2010 Mar 27.

8.

Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors.

Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM.

Menopause. 2010 Jan-Feb;17(1):178-84. doi: 10.1097/gme.0b013e3181afcce5.

9.

Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.

Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM.

Endocr Relat Cancer. 2009 Mar;16(1):85-98. doi: 10.1677/ERC-08-0069. Epub 2008 Dec 15.

PMID:
19075036
10.

Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.

Liang Y, Besch-Williford C, Benakanakere I, Hyder SM.

Int J Oncol. 2007 Oct;31(4):777-84.

PMID:
17786308
11.

Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.

Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM.

Clin Cancer Res. 2006 Jul 1;12(13):4062-71.

Supplemental Content

Loading ...
Support Center